David J. Wambeke is Chief Business Officer at DiaMedica Therapeutics Inc. (DMAC). They have made 5 open-market trades across 2 companies since 2023, most recently 2026-08-27.
CIK 0001971798
5 open-market purchases totalling $1.8M since 2023, never a sale. Across 5 scored buys the stock is down 11.5% at thirty days, and 13.1 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| DMAC | 527,114 | $4.0M |
| NMTC | 199,999 | $194K |
| Total | $4.2M |
Shares reported on the most recent Form 4, priced at the 2026-09-08 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 20% | 20% | — |
| Avg Move | -7.6% | -11.5% | — |
| Alpha | -7.4% | -13.1% | — |
| Scored | 5 | 5 | 4 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NMTC | BUY | 2026-08-27 | 2026-09-08 | $2.01 | $67K | -18.5% | -33.9% | — |
| NMTC | BUY | 2026-03-01 | 2026-03-03 | $0.67 | $670K | -9.5% | -4.2% | +348.2% |
| DMAC | BUY | 2023-11-16 | 2023-11-16 | $2.46 | $49K | +2.9% | +13.2% | +21.4% |
| DMAC | BUY | 2023-06-23 | 2023-06-26 | $3.91 | $300K | -11.1% | -25.1% | -42.1% |
| DMAC | BUY | 2023-04-10 | 2023-04-11 | $1.60 | $750K | -1.7% | -7.4% | +111.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.